Want to see VOR full AI Analyst Report?
Top Page
Vor Biopharma
(NASDAQ:VOR)
Select Model
Select Model
Rating:41Neutral
Price Target:
$18.50
▼(-22.95% Downside)
Action:Reiterated
Date:09/24/26
The score is primarily held down by weak financial performance (pre-revenue profile with persistent operating losses, heavy cash burn, and materially negative equity) and bearish technical momentum (below key moving averages with a negative MACD). Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Low absolute debt
Very modest absolute debt reduces interest and refinancing pressure relative to a heavily leveraged company. This gives Vor greater flexibility to direct available capital toward clinical development and preserves some capacity to manage financing needs as programs advance.
Negative Factors
Pre-revenue business
Zero revenue means Vor has not yet demonstrated commercial product demand or an operating revenue base. The company therefore remains dependent on clinical progress and external capital rather than internally generated sales to support its business and development plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Low absolute debt
Very modest absolute debt reduces interest and refinancing pressure relative to a heavily leveraged company. This gives Vor greater flexibility to direct available capital toward clinical development and preserves some capacity to manage financing needs as programs advance.
Read all positive factors
Vor Biopharma (VOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.17B
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)5.02
Revenue GrowthN/A
EPS Growth69.48%
CountryUS
Employees76
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-325.79
Shares Outstanding59,162,292
10 Day Avg. Volume922,690
30 Day Avg. Volume1,132,212
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.16K
Enterprise Value/Ebitda0.83
Forecast
1Y Price Target
$37.67Price Target Upside56.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-7.21
Revenue Forecast (FY)N/A
Vor Biopharma Business Overview & Revenue Model
Company Description
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently unde...
How the Company Makes Money
Vor Biopharma is a clinical-stage biopharmaceutical company and does not have approved products; therefore, recurring product revenue from marketed therapies is null. The company’s funding and cash inflows have historically been primarily generate...
Vor Biopharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -28.00K | 0.00 | 0.00 | -3.49M | -8.96M | 0.00 |
| EBITDA | 642.83M | -693.09M | -113.39M | -114.37M | -89.57M | -67.47M |
| Net Income | 627.78M | -695.98M | -116.91M | -117.86M | -92.09M | -68.90M |
Balance Sheet | ||||||
| Total Assets | 481.05M | 464.13M | 142.89M | 209.83M | 299.37M | 242.59M |
| Cash, Cash Equivalents and Short-Term Investments | 466.13M | 455.21M | 91.93M | 137.18M | 230.25M | 207.47M |
| Total Debt | 2.88M | 3.00M | 31.83M | 35.66M | 38.91M | 18.01M |
| Total Liabilities | 681.25M | 628.44M | 46.23M | 59.10M | 48.76M | 26.33M |
| Stockholders Equity | -200.20M | -164.31M | 96.66M | 150.72M | 250.61M | 216.26M |
Cash Flow | ||||||
| Free Cash Flow | -141.11M | -143.65M | -99.89M | -101.36M | -93.61M | -73.04M |
| Operating Cash Flow | -140.38M | -142.71M | -99.66M | -100.29M | -85.14M | -69.14M |
| Investing Cash Flow | -348.99M | -48.80M | 96.86M | 71.01M | -94.09M | -91.65M |
| Financing Cash Flow | 404.24M | 503.81M | 53.39M | 2.94M | 117.14M | 232.91M |
Vor Biopharma Technical Analysis
Positive
24.01
Price Trends
21.84
Negative
19.29
Positive
16.92
Positive
Market Momentum
-0.77
Negative
47.30
Neutral
75.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Positive. The current price of 24.01 is above the 20-day moving average (MA) of 19.74, above the 50-day MA of 21.84, and above the 200-day MA of 16.92, indicating a neutral trend. The MACD of -0.77 indicates Negative momentum. The RSI at 47.30 is Neutral, neither overbought nor oversold. The STOCH value of 75.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VOR.
Vor Biopharma Risk Analysis
Vor Biopharma disclosed 77 risk factors in its most recent earnings report. Vor Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vor Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $403.43M | -2.42 | -64.25% | ― | ― | -29.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $101.69M | -2.39 | -38.80% | ― | -100.00% | -392.92% | |
47 Neutral | $154.40M | -4.20 | -74.36% | ― | 35.89% | 58.70% | |
47 Neutral | $384.05M | -2.11 | -81.91% | ― | ― | 20.07% | |
41 Neutral | $1.17B | -0.06 | -91.63% | ― | ― | 69.48% | |
41 Neutral | $53.27M | -0.46 | -89.11% | ― | 10.02% | 39.66% |
* Healthcare Sector Average
VOR
Vor Biopharma
19.80
-12.49
-38.68%
CDXS
Codexis
1.41
-1.09
-43.60%
BDTX
Black Diamond Therapeutics
1.77
-2.03
-53.42%
AVIR
Atea Pharmaceuticals
5.03
1.92
61.74%
CRBU
Caribou Biosciences
0.50
-1.88
-79.16%
KYTX
Kyverna Therapeutics, Inc.
6.21
-0.72
-10.39%
Vor Biopharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
Positive
Jul 7, 2026
On July 6, 2026, Vor Biopharma announced that Board member Andrew Levin, M.D., Ph.D., resigned effective immediately, with the company noting his departure did not stem from any disagreement. The Board expressed appreciation for his service, indic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.